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Abstract: In the past few years, there has been increasing focus on the use of messenger RNA
(mRNA) as a new therapeutic modality. Current clinical efforts encompassing mRNA-based drugs are
directed toward infectious disease vaccines, cancer immunotherapies, therapeutic protein replacement
therapies, and treatment of genetic diseases. However, challenges that impede the successful
translation of these molecules into drugs are that (i) mRNA is a very large molecule, (ii) it is
intrinsically unstable and prone to degradation by nucleases, and (iii) it activates the immune system.
Although some of these challenges have been partially solved by means of chemical modification of
the mRNA, intracellular delivery of mRNA still represents a major hurdle. The clinical translation
of mRNA-based therapeutics requires delivery technologies that can ensure stabilization of mRNA
under physiological conditions. Here, we (i) review opportunities and challenges in the delivery of
mRNA-based therapeutics with a focus on non-viral delivery systems, (ii) present the clinical status of
mRNA vaccines, and (iii) highlight perspectives on the future of this promising new type of medicine.
Keywords: mRNA; vaccines; therapeutic; prophylactic; drug delivery systems; lipids; polymers;
nanoparticles; nanomedicine
1. Introduction
Vaccination has had a tremendous impact on global health and the quality of human life by reducing
the mortality and morbidity caused by infectious diseases. The development of vaccines is predicated
on the classical 3I’s paradigm of “isolating, inactivating and injecting” the causative microorganism,
coined by Louis Pasteur [1]. Vaccines can be prophylactic or therapeutic and can broadly be classified
as live attenuated vaccines (weakened microorganisms), inactivated vaccines (killed microorganisms),
subunit vaccines (purified antigens), or toxoid vaccines (inactivated bacterial toxins). As opposed to the
conventional concept of injecting live-attenuated or inactivated pathogens, modern vaccine approaches,
i.e., subunit vaccines, focus on exhibiting efficacy similar to conventional vaccines while obviating
the safety risks associated with whole-cell vaccines. However, subunit antigens often display lower
immunogenicity, which can be rectified by employing delivery systems and/or immunopotentiating
compounds as adjuvants to boost immunogenicity. The modern genome-based rational vaccine design
offers tremendous potential over conventional whole-organism-based vaccine approaches.
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Nucleic acid-based vaccines, i.e., DNA (as plasmids) and RNA (as messenger RNA (mRNA))
vaccines, pave the way for safe and efficacious biologics to mimic inoculation with live organism-based
vaccines, particularly for stimulation of cell-mediated immunity [2]. This technology exhibits promising
potential for the development of novel vaccines against a wide variety of indications and diseases,
extending from prophylactics to therapeutics for infectious diseases, cancer, autoimmune diseases,
and hypersensitivities. While nucleic-acid-based vaccines demonstrate significant advantages over
traditional vaccines [3] in terms of safety, efficacy, induction of both B- and T-cell responses and
specificity, it is noteworthy to mention that mRNA vaccines have advantages when compared to
vaccines based on other types of nucleic acids. A technical challenge associated with DNA vaccines
is to ensure delivery into the cell nucleus, where antigen transcription takes place prior to nuclear
export and translation into protein in the cytoplasm. In addition, DNA vaccines carry a potential risk
of integration into the host genome, which may result in insertional mutagenesis. In contrast, mRNA
vaccines are only targeted for cytoplasmic delivery, circumventing the risk of genomic integration [4].
The relatively short half-life results in transient and more controlled expression of the encoded antigen.
Moreover, mRNA can be produced in a cell-free environment by in vitro transcription (IVT), thereby
eschewing the use of microbes or cultured cells for production, and avoiding the associated quality
and safety issues in the production. This permits simple downstream purification and rapid and
cost-effective manufacturing [5]. However, mRNA is often promulgated on the grounds of the popular
opinion that when using mRNA, unlike DNA, the stringent gene-therapy regulations are bypassed
because mRNA does not integrate into the host genome. However, in reality, this only holds true in the
US since in Europe, any active pharmaceutical ingredient, which contains or consists of a recombinant
nucleic acid, used in or administered to human beings, falls under the scope of the regulation for
advanced therapy medicinal products [6]. Therefore, mRNA-based therapeutics are categorized as
gene therapy. The burgeoning field of mRNA vaccines is very exciting [3,7] and considerable amounts
of relevant preclinical data have been generated, and several clinical trials have been initiated during
the last decade. This gives rise to the vision of translating the mRNA vaccines into human application
for prophylaxis and therapy. In this review, we discuss the current trends in mRNA vaccine approaches
and various strategies and systems for delivering mRNA vaccines.
2. mRNA as Vaccines
The central dogma of molecular biology states that DNA is transcribed into mRNA, which
is subsequently translated into protein [8]. The flow of genetic information in time and space is
orchestrated by complex regulatory mechanisms. Gene therapy represents the introduction of genetic
material into an individual’s cells and biological tissues. Techniques like insertion, alteration, or
removal of genes are employed for correcting defective genes responsible for disease development,
which then cures a disease or ameliorates the clinical status of a patient [9]. Several vectors have been
utilized for gene therapy and they are generally classified as non-viral and viral vectors. Non-viral
vectors possess several advantages compared to the viral vectors, including low host immunogenicity
and potential for scale-up [10]. However, the success of non-viral gene therapy has been very limited in
the past, primarily due to the barriers existing for plasmid DNA (pDNA) delivery, e.g., the necessity to
cross the nuclear membrane before translation, the presence of antibiotic resistance genes in pDNA, and
most importantly, the difficulty in controlling and regulating long-term expression. The lack of control
of long-term expression of pDNA poses a huge disadvantage in terms of the duration of treatment and
possible side effects, which is in contrast to conventional drugs, where the treatment can be stopped
instantaneously. These disadvantages of pDNA can possibly be overcome by using mRNA [11]. The
mRNA carries genetic information from the DNA in the nucleus to the cytosol, where it is used by the
ribosomes as a template for protein synthesis. As opposed to pDNA, the mRNA is efficacious in both
mitotic and non-mitotic cells because mRNA exerts its function in the cytoplasm, hence its function
is not dependent on active cell division. Furthermore, unlike pDNA or viral vectors, mRNA does
not contain additional foreign genes, which makes mRNA a safer vector. The challenge of long-term
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expression posed by pDNA can also be overcome by using mRNA, since mRNA mediates a rapid,
transient expression of the encoded protein and the duration of the production is well-defined (usually
a few days or weeks, depending on the specific mRNA platform). This makes mRNA expression easier
to control than the gene expression from pDNA and viral vectors [11]. In addition, the manufacturing
of mRNA is cell-free, which strongly reduces the chance of mRNA contamination with bacterial
components. This makes it easier to produce mRNA than pDNA under good manufacturing practice
conditions [12]. Finally, vector-induced immunogenicity can be avoided for mRNA therapeutics, unlike
for viral vectors or virus-like particles, which may elicit a specific immune response against the exposed
viral proteins [13]. Specific therapeutic applications of mRNA, which are currently being explored
include (i) vaccination against cancer and infectious diseases, (ii) protein-replacement therapy, and (iii)
gene editing. Table 1 summarizes examples of ongoing clinical trials of mRNA-based therapeutic and
prophylactic vaccine candidates.
Two classes of mRNAs, i.e., non-replicating and self-amplifying mRNA, are commonly used as vaccine
vectors. Non-replicating mRNA encodes only the protein antigen(s) of interest, while self-amplifying
mRNA also encodes proteins enabling RNA replication [14]. Vaccines based on self-amplifying mRNA
encode the RNA genome of a single-stranded RNA virus, e.g., an alphavirus, a flavivirus [15], or a
picornavirus [7]. They are engineered to increase the duration and level of expression, as well as the
subsequent immune response induced by the encoded antigen(s). They efficiently amplify the production
of sub-genomic mRNA encoding antigen(s) of interest subsequent to a single round of replication. While
both self-amplifying mRNA and non-replicating mRNA find application in prophylactic vaccines for
infectious diseases, non-replicating mRNA is used for cancer vaccines.
3. Fundamental Pharmacology of mRNA Vaccines
In vitro transcribed (IVT) mRNA is employed therapeutically as it mimics fully mature native
mRNA present in the eukaryotic cytosol [16]. This may be achieved either by ex vivo transfection of cells
with mRNA that are then adoptively transferred or by direct in vivo delivery of the IVT mRNA to the
cytosol [17]. These approaches are explored for genome engineering, genetic reprogramming, adoptive
T cell and dendritic cell (DC) based cancer and infectious disease immunotherapies, tolerization
regimens to treat allergies, and protein replacement therapies. Both ex vivo transfection and direct
in vivo transfection enable the target cells to synthesize the encoded protein(s) in situ, where mRNA is
used as a template and the protein(s) represents the active product. The open reading frame (ORF)
of mature mRNA encoding the protein(s) of interest (the active product) marked by start and stop
codons, respectively, is flanked by untranslated regions (UTRs), and ideally consists of a 5’ cap and a
poly(A) tail [3].
The pharmacodynamic activity of both native and IVT mRNA takes place in the cytosol (Figure 1).
However, in contrast to endogenous mRNA, which is transcribed from DNA in the nucleus and enters
the cytosol through nuclear export, IVT mRNA enters the cytosol from an extracellular source [18].
Once the IVT mRNA is delivered to the cytosol, its pharmacology is governed by the same complex
cellular mechanisms that regulate the stability and translation of endogenous mRNA. The engineered
IVT mRNA resembles the endogenous mRNA so closely that the cellular translation machinery
is seamlessly utilized to synthesize a protein that may undergo post-translational modifications,
eventually resulting in mature protein product(s). In the case of vaccines, this mature protein product(s)
represents the antigen(s), which may elicit potent pathogen-specific humoral and cell-mediated immune
responses. However, the final intracellular destination is determined by the natural or engineered
sequence(s) of the signal peptide or the transmembrane domain [7]. Therefore, mRNA vaccines can be
designed for the delivery of the encoded protein(s) to the desired cellular compartment for proper
presentation and/or function [19].
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Table 1. Examples of ongoing clinical trials of mRNA-based vaccines.
mRNA Mechanism ofAction Disease/Condition
Administration
Route Study Phase Sponsor/Collaborator
National Clinical
Trial Identifier
Therapeutic
mRNA
W_ova1 vaccine
Induction of an
anti-tumor immune
response
Ovarian cancer Intravenous Phase I University Medical CenterGroningen/BioNTech NCT04163094
CT7, MAGE-A3, and WT1
mRNA-electroporated
Langerhans cells (LCs)
Electroporation of
dendritic cells with
antigen mRNA
Multiple Myeloma Subcutaneous Phase I Memorial Sloan KetteringCancer Center NCT01995708
Personalized Cellular
mRNA
Immunization with
DCs pulsed with
mRNA encoded
tumor antigens
Brain
cancer/Neoplasm
Metastases
Not specified Phase I
Guangdong 999 Brain
Hospital/Beijing, Tricision,
Trinomab, Jinan University
Guangzhou
NCT02808416
Personalized mRNA
Immunization with
DCs pulsed with
personalized mRNA
Glioblastoma Not specified Phase I
Guangdong 999 Brain
Hospital/Beijing Tricision,
Trinomab, Jinan University
Guangzhou
NCT02808364
MiHA mRNA
Immunization with
DCs loaded with
MiHA mRNA
Hematological
malignancies Intravenous
Phase I
Phase II
Radboud
University/ZonMw:
The Netherlands
Organization for Health
Research and Development
Dutch Cancer Society
NCT02528682
WT1-mRNA
Immunization with
DCs electroporated
with WT1-mRNA
Acute myeloid
leukemia Not Specified Phase II
Zwi Berneman/Kom Op
Tegen Kanker
stichting tegen kanker
Research Foundation -
Flanders (FWO: Fonds
Wetenschappelijk
Onderzoek)
NCT01686334
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Table 1. Cont.
mRNA Mechanism ofAction Disease/Condition
Administration
Route Study Phase Sponsor/Collaborator
National Clinical
Trial Identifier
Therapeutic
mRNA
Human CMV
pp65-LAMP mRNA
Immunization with
DCs pulsed with
CMV pp65-LAMP
mRNA
Glioblastoma Intradermal Phase II Gary Archer Ph.D./DukeUniversity NCT03927222
Personalized mRNA
Personalized mRNA
tumor vaccine
encoding neoantigen
Advanced esophageal
squamous carcinoma,
gastric
adenocarcinoma,
pancreatic
adenocarcinoma,
colorectal
adenocarcinoma
Subcutaneous Enrolling
Changhai
Hospital/Stemirna
Therapeutics
NCT03468244
mRNA[BI 1361849
(formerly CV9202)] Not specified
Metastatic non-small
cell lung cancer Not specified Phase I Phase II
Ludwig Institute for Cancer
Research/Cancer Research
Institute, New York City,
Boehringer Ingelheim
MedImmune, CureVac,
PharmaJet
NCT03164772
mRNA-5671/V941 Not specified
Neoplasms,
carcinoma,
non-small-cell lung,
pancreatic neoplasms,
colorectal neoplasms
Intramuscular Phase I Merck Sharp & Dohme NCT03948763
mRNA-4157 Immunostimulants Solid tumors Not specified Phase I Moderna/Merck Sharp &Dohme NCT03313778
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Table 1. Cont.
mRNA Mechanism ofAction Disease/Condition
Administration
Route Study Phase Sponsor/Collaborator
National Clinical
Trial Identifier
Therapeutic
mRNA
mRNA-4157
Immunotherapy with
the personalized
cancer vaccine
Cutaneous melanoma Not specified Phase II Moderna/Merck Sharp &Dohme NCT03897881
Personalized mRNA Encoding neoantigen
Esophageal cancer
Non-small cell lung
cancer
Subcutaneous Enrolling
Stemirna Therapeutics/The
First Affiliated Hospital of
Zhengzhou University
NCT03908671
mRNA-3704
Alpha-galactosidase
stimulants;
Methylmalonyl CoA
mutase stimulants;
Protein synthesis
stimulants
Methylmalonic
acidemia, metabolism,
inborn errors
Intravenous Phase IPhase II Moderna NCT03810690
mRNA-2416 OX40 ligandmodulators
Relapsed/Refractory
solid tumor
malignancies or
lymphoma
Intratumoral Phase I Moderna NCT03323398
mRNA-2752
IL36G protein
stimulants;
Interleukin 23
stimulants; OX40
ligand modulators
Relapsed/Refractory
solid tumor
malignancies or
lymphoma
Intratumoral Phase I Moderna/AstraZeneca NCT03739931
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Table 1. Cont.
mRNA Mechanism ofAction Disease/Condition
Administration
Route Study Phase Sponsor/Collaborator
National Clinical
Trial Identifier
Prophylactic mRNA
mRNA-1647, mRNA-1443 Not specified Cytomegalovirus Not specified Phase I Moderna NCT03382405
mRNA-1893 Not specified Zika virus Not specified Phase I
Moderna/Biomedical
Advanced Research and
Development Authority
NCT04064905
mRNA-1653
A combined human
metapneumovirus
and human
parainfluenza virus
type 3 vaccine
Human
metapneumovirus
and Human
Parainfluenzavirus
Not specified Phase I Moderna. NCT03392389NCT04144348
mRNA-1944
Encoding for an
anti-Chikungunya
virus monoclonal
antibody
Chikungunya virus Parenteral Phase I Moderna NCT03829384
mRNA-1653 Immunostimulants
Metapneumovirus
and Parainfluenza
virus
Parenteral Phase I Moderna NCT03392389
CV7202 Immunostimulants Rabies Intramuscular Phase I CureVac NCT03713086
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Figure 1. Mechanism of action of mRNA vaccines. 1. The mRNA is in vitro transcribed (IVT) from a 
DNA template in a cell-free system. 2. IVT mRNA is subsequently transfected into dendritic cells 
(DCs) via (3) endocytosis. 4. Entrapped mRNA undergoes endosomal escape and is released into the 
cytosol. 5. Using the translational machinery of host cells (ribosomes), the mRNA is translated into 
antigenic proteins. The translated antigenic protein undergoes post-translational modification and 
can act in the cell where it is generated. 6. Alternatively, the protein is secreted from the host cell. 7. 
Antigen protein is degraded by the proteasome in the cytoplasm. The generated antigenic peptide 
epitopes are transported into the endoplasmic reticulum and loaded onto major histocompatibility 
complex (MHC) class I molecules (MHC I). 8. The loaded MHC I-peptide epitope complexes are 
presented on the surface of cells, eventually leading to the induction of antigen-specific CD8+ T cell 
responses after T-cell receptor recognition and appropriate co-stimulation. 9. Exogenous proteins are 
taken up DCs. 10. They are degraded in endosomes and presented via the MHC II pathway. 
Moreover, to obtain cognate T-cell help in antigen-presenting cells, the protein should be routed 
through the MHC II pathway. 11. The generated antigenic peptide epitopes are subsequently loaded 
onto MHC II molecules. 12. The loaded MHC II-peptide epitope complexes are presented on the 
surface of cells, leading to the induction of the antigen-specific CD4+ T cell responses. Exogenous 
antigens can also be processed and loaded onto MHC class I molecules via a mechanism known as 
cross-presentation (not shown in the figure). The figure was created with BioRender.com. 
The pharmacokinetics of IVT mRNA is determined by the half-life of the mRNA and the 
resulting mature protein after post-translational modification. The two major factors influencing the 
bioavailability of exogenous mRNA in the cytosol are (i) rapid RNase-mediated degradation and (ii) 
lack of passive diffusion across the plasma membrane owing to high molecular weight and 
electrostatic repulsion between the negative charges of the proteoglycan-coated cell membrane and 
the negatively-charged mRNA molecules [20]. Naked mRNA is rapidly degraded by extracellular 
RNases, thus hindering its efficient delivery and efficacy. A wide range of in vitro and in vivo 
transfection reagents have been shown to protect the mRNA against degradation and facilitate the 
Figure 1. Mechanism of action of mRNA vaccines. 1. The mRNA is in vitro transcribed (IVT) from a
DNA template in a cell-free system. 2. IVT mRNA is subsequently transfected into dendritic cells (DCs)
via (3) endocytosis. 4. Entrapped mRNA undergoes endosomal escape and is released into the cytosol.
5. Using the translational machinery of host cells (ribosomes), the mRNA is transl ted into antigenic
proteins. The translated tig nic prote n undergoes post-translational modification and can act in
the cell where it is g nerated. 6. Alternativ ly, h prot in is secret d from the host cell. 7. Antigen
protein is degraded by the proteasome in the cytoplasm. The generated antigenic peptide itopes are
transported into the en oplasmic reticulu and loaded o to major histocompatibility complex (MHC)
class I molecules (MHC I). 8. The loaded MHC I-peptide epitope complexes are presented on the
surface of cells, eventually leading to the induction of antigen-specific CD8+ T cell responses after T-cell
receptor recognition and appropriate co-stimulation. 9. Exogenous proteins are taken up DCs. 10. They
are degraded in endosomes and presented via the MHC II pathway. Moreover, to obtain cognate T-cell
help in antigen-presenting cells, the protein should be routed through the MHC II pathway. 11. The
generated antigenic peptide epitopes are subsequently loaded onto MHC II molecules. 12. The loaded
MHC II-peptide epitope complexes are presented on the surface of cells, leading to the induction of
the antigen-specific CD4+ T cell responses. Exogenous antigens can also be processed and loaded
onto MHC class I molecules via a mechanism known as cross-presentation (not shown in the figure).
The figure was created with BioRender.com.
The pharmacokinetics of IVT mRNA is determined by the half-life of the mRNA and the
resulting mature protein after post-translational modification. The two major factors influencing
the bi availability of exogen us mRNA in the cytosol are (i) rapid RNase-mediat d degradation
and (ii) l ck of pa sive diffusion across the plasma memb ane owing to high mol cular weight and
electrostatic repulsion between th negative ch rges of the proteog can-coated cell membr ne and
the negatively-charged mRNA molecul s [20]. Naked mRNA is pidly degraded by extracellular
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RNases, thus hindering its efficient delivery and efficacy. A wide range of in vitro and in vivo
transfection reagents have been shown to protect the mRNA against degradation and facilitate the
cellular uptake and endosomal escape of mRNA. Major efforts have been dedicated to improving the
enzymatic RNA stability, as discussed further below [3]. Ultimately, the IVT mRNA composed of
natural nucleotides is metabolized by inherent physiological mechanisms, hence reducing the risk of
metabolite-induced toxicity. Therefore, the delivery issues can be overcome by approaches including
encapsulation of mRNA in drug delivery systems consisting of cationic molecules, lipids, polymers,
and nanoparticles [21] as well as targeting DCs [22]. In addition, physical transfection methods
like electroporation have been shown to enhance the delivery efficiency of large, self-amplifying
mRNA in vivo, upon measuring reporter gene expression and immunogenicity of genes encoding HIV
envelope proteins [23].
4. Approaches for Enhancing mRNA Stability
The development of mRNA-based drugs dates back to 1990 with the successful expression of a
number of different proteins upon injecting mRNA encoding these proteins directly into the muscles
of mice [24]. This led to (i) the testing of the first mRNA-based vaccine in 1993, which was shown to
induce an anti-influenza cytotoxic T-lymphocyte response in mice [25], and (ii) the first vaccination with
mRNA-encoding cancer antigens in 1995 [26]. These inceptive demonstrations ratified the potential of
mRNA for (i) in situ expression of specific proteins and (ii) for induction of protective antigen-specific
cellular and humoral immunity. However, the field was neglected for almost ten years until the
potential of in vivo application of mRNA, i.e., induction of specific cytotoxic T lymphocytes and
antibodies, was discovered [27]. Advances in the mRNA field were slow due to the labile nature of
mRNA, which makes experiments employing unmodified mRNA very challenging unless precautions
to handle mRNA are strictly adhered to [28]. Instead, the focus was directed towards DNA-based
drugs, since DNA is more stable than RNA.
In a cell-free system, mRNA can be synthesized by IVT of a DNA template (e.g., a linearized
plasmid or a PCR product), which encodes all the structural elements of a functional mRNA. To perform
an IVT reaction, all the elements of the natural transcription process are required, i.e., a DNA template,
an RNA polymerase, and nucleotide building blocks. During the subsequent purification of the mRNA,
the DNA template is often degraded by the addition of DNases, followed by purification by means of
other conventional methods for isolating mRNA, e.g., precipitation and chromatography. This process
results in highly pure mRNA products ready for use [29–31]. Several strategies have been pursued
to cope with mRNA’s inherent lack of stability and potential immunogenicity, which are discussed
further below.
4.1. Molecular Stabilization
Strategies including engineering of sequences and/or structure to enhance mRNA stability
(extend the half-life) and translation are often instrumental in increasing the protein expression levels.
Techniques employed to achieve this includes elongation of the poly(A) tail, modification of the 5’ cap,
engineering of the UTRs and the sequence patterns in the ORF, and/or incorporation of modified
nucleotides (Figure 2).
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A synthetic cap analogue can readily be added to the mRNA because the 5’ end cap is not 
encoded by the DNA template. Natural eukaryotic mRNA has a 7-methylguanosine (m7G) cap 
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the competition between the cap analog and the GTP nucleotide required for in vitro transcription, 
which ultimately results in a fraction of uncapped and translationally inactive mRNA [36]. The 
fraction of uncapped mRNA containing 5’ ppp groups is more immune-stimulating, which can be 
rectified by treatment with phosphatase to remove the ppp group at the 5’ end of uncapped mRNA 
[37].  
Three different classes of m7GpppG cap analogs are used [38]: (i) anti-reverse cap analogs 
(ARCAs) [39], (ii) 3’-O-Me-m7GpppG [40], and (iii) modified ARCAs [41]. Initial mRNA research was 
performed using mRNA containing the m7 cap analog (GpppG) [42], and it is currently the most 
commonly used mRNA cap in clinical trials. Unfortunately, a fraction of the m7GpppG cap analog 
used during in vitro transcription becomes incorporated in the opposite orientation and is therefore 
Figure 2. Structure of in vitro transcribed (IVT) mRNA and commonly used modification strategies.
The design of IVT mRNA is based on the blueprint of eukaryotic mRNA, and it consists of a 5’ cap, 5’ and
3’ untranslated regions (UTRs), an open reading frame (ORF) encoding antigen(s), and a 3’ poly(A) tail.
The IVT mRNA can be modified in one or multiple sites, e.g., by modification of the caps, the UTRs
and/or the poly(A) tail, to modulate the duration and kinetic profile of protein expression. eIF4E,
eukaryotic translation initiation factor 4E.
4.1.1. Cap Analog
A synthetic cap analogue can readily be added to the mRNA because the 5’ end cap is not encoded
by the DNA t mpl te. N tural eukaryotic mRNA has a 7-methylguanosine (m7G) cap coupled to the
mRNA during the transcription process via a 5’-5’-triphosphate bridge (ppp) [32]. Th m7GpppN
str cture at the 5’ end of the mRNA cap serves several functions [33]. Firs , it protects the mRNA
from ra id degradation by exonucleases. Second, it plays an indispensable role during t anslation
because the euk ryotic initiation factor (eIF) 4E recognizes and binds to the cap of the mRNA. It further
pl y r le in preventing innate immune se sors f om recognizin th mRNA [34]. The mRNA may
contain one of th ee di tinct caps, i.e., cap-0 [m7G(5’)pppN1pN2p], cap-1 [m7G(5’)pppN1 p p] and
cap-2 [m7G(5’)pppN1mpN2mp], respectively [11]. C ping of IVT mRNA can be performed using
two different approaches: The first approach includes the addition of a second step with recombinant
vaccinia virus-derived capping enzymes after the t anscription, re ulting in a cap identical to the most
freque t endogenous ukaryotic cap structure i.e., 7-m thylgua osine (m7G) cap [30]. Alternatively
a syn hetic cap analogue m y be added during th in vitro transcription eaction, hence apping and
in vitro transcription is performed in a single step. This approach is ref rred to as co-transcriptional
capping [35]. A major drawback of this approach is the competition betwe n the cap analog and the
GTP nucleotide requi ed for in vitro transcription, which ultimately results in a fraction of uncapped
and translationally inactive mRNA [36]. The fraction of uncapped mRNA contai ing 5’ ppp groups is
more immune-stimulating, which an be rectified by treatment with phosph tase to remove the ppp
g oup at the 5’ end of uncapped mRNA [37].
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Three different classes of m7GpppG cap analogs are used [38]: (i) anti-reverse cap analogs
(ARCAs) [39], (ii) 3’-O-Me-m7GpppG [40], and (iii) modified ARCAs [41]. Initial mRNA research
was performed using mRNA containing the m7 cap analog (GpppG) [42], and it is currently the
most commonly used mRNA cap in clinical trials. Unfortunately, a fraction of the m7GpppG cap
analog used during in vitro transcription becomes incorporated in the opposite orientation and
is therefore not recognized by the ribosomes, eventually resulting in lower translational activity.
To avoid this, the so-called ARCA with only one 3’-OH group instead of two 3’-OH groups (ARCAs;
m27,3’−OGpppG) has been introduced to prevent incorporation in the opposite orientation [43].
ARCAs juxtaposing the traditional cap analogues have been shown to exhibit more than four times
RNA transcription efficiency [44]. In addition, the duration and the levels of protein expression
have been found to be enhanced in cells transfected with ARCA-capped IVT RNA [41]. Recently,
new types of chemically-modified cap analogues have been introduced, e.g., of phosphorothioate,
phosphorothiolate [35], imidiphosphate [45], locked nucleic acid [46], boranophosphate bonds [47]
and other types of modifications, which provide the mRNA with resistance to decapping by the
mRNA-decapping enzyme 2, eventually resulting in a longer half-life of the mRNA [48].
Conventionally, the synthetic 5’-Cap 0-capped RNA is transcribed by performing an in vitro
transcription, where more than 80% of the GTP added to the reaction is substituted with a dinucleotide
cap analog (i.e., m7G[5’]ppp[5’]G), resulting in initiation of transcription with the cap analog [49].
However, this approach has been shown to exhibit a number of efficiency-related drawbacks, which have
been overcome by the introduction of ScriptCap™. ScriptCap™ involves the addition of enzymatically
built cap-0 structures onto the RNA transcripts by employing a capping enzyme with 100% reaction
efficiency [50]. Native eukaryotic mRNA may contain a cap-1 or cap-2 but never a cap-0 [11]. Therefore,
IVT mRNA should contain a cap-1 or a cap-2 in order to be less immune-stimulating [51]. A hallmark
of these cap structures is the methylation status of the 2’ position of the 5’ second last and third last
nucleoside. Prior to the advent of the novel technology of CleanCap™ introduced by TriLink, synthetic
mRNA with a cap-1 could only be prepared by enzymatic capping [52,53]. However, cap-1 or cap-2
can now be incorporated during co-transcriptional capping at a capping efficiency of approximately
94% [52]. Notably, the capping efficiency has been shown to be significantly higher than the efficiency
achieved by traditional co-transcriptional capping with cap-0 or ARCA [54].
4.1.2. 5’ and 3’ Untranslated Regions (UTRs)
The importance of incorporation of 5’- and 3’-UTRs has been noted during in vitro
post-transcriptional regulation of gene expression [55]. The numerous roles that UTRs play include
(i) regulation of mRNA export from the nucleus, (ii) regulation of translation efficiency [56],
(iii) orchestration of subcellular localization [57], and (iv) mRNA stability [58]. Introduction of
α-globin 3’ end UTRs results in stabilization of mRNA, while the incorporation of beta-globin 5’ end
and 3’ end UTRs leads to enhanced translational efficiency [59]. The optimal outcome is achieved
by using two β-globin 3’-UTRs aligned in a head-to-tail configuration. α-globin and β-globin UTRs
have been incorporated for tweaking the RNA for optimized in vitro transcription followed by
mRNA electroporation of autologous T cells [60] and intranodal injection of naked antigen-encoding
RNA [61]. Moreover, DCs transfected with antigen-encoding UTR-optimized mRNA have been used in
a study involving immunization of cytomegalovirus-seropositive individuals and cancer patients [62].
In some situations, destabilizing the mRNA might be a viable approach to reduce the duration of
protein synthesis. This may be accomplished by introducing adenylate-uridylate-rich elements in
the 3’-UTRs of the mRNA, eventually resulting in faster mRNA degradation and shortening of the
duration of protein expression [63].
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4.1.3. Poly(A) Tail
The poly(A) tail plays a significant role in mRNA translation as well as for the enzymatic
stability of mRNA. The poly(A) tail binds to several polyadenosyl binding proteins (PABPs) while
working synergistically with 5’m7Gcap sequences to regulate translational efficiency [64]. Eukaryotic
translation initiation factor eIF4E binds to the 5’m7G cap, which in turn complexes with eIF4G and
eIF4A. PABP then interacts with the N-terminus of the eukaryotic translation initiation factor eIF4G,
which forms an mRNP (messenger ribonucleoprotein) or a polysome complex [65]. The former depicts
the mRNA-protein complex not yet involved in protein synthesis, while the latter is one that is already
being translated. An adequately long poly(A) tail is required to circularize the mRNA via binding
of PABPs to the poly(A) tail and the cap [55,66]. It has been observed that increasing the poly(A)
tail length improves the efficiency of polysome generation and consequently influences the protein
expression levels [67].
It has been shown that a gradual increase in the poly(A) tail length of IVT mRNA to 120 bases
commensurately increases the protein expression level, while an increase in the number of bases
beyond 120 does not further enhance protein expression [68]. Poly(A) tails can be added to mRNA by
encoding the poly(A) tail in the DNA template, or by extension of the IVT RNA after transcription using
recombinant poly(A) polymerase. However, polyadenylation with recombinant poly(A) polymerase
results in variable poly(A) tail length, thereby yielding polyadenylated mRNA with varying lengths.
Therefore, the preferred approach is the generation of poly(A) tails with well-defined length from
the mRNAs transcribed from poly(A) tail-encoding DNA templates [69]. The physical interactions
between the 5’ and 3’ ends of mRNA take place between the cap and the poly(A) tail [70]. The poly(A)
tail also plays a role in preventing decapping and mRNA degradation because removal or shortening
of the poly(A) tail to less than 12 residues results in degradation of the mRNA through cleavage of the
5’ cap structure and 5’ to 3’ exonucleolytic digestion or 3’ to 5’ degradation [71].
4.2. Formulation Strategies
Despite the promising potential of mRNA-based vaccines, efficient intracellular delivery of mRNA
to the cytosol continues to pose a major hurdle, especially for mRNA administered systemically.
The large molecular weight (105–106 Da) [21] and high negative charge density of mRNA impair the
permeation of mRNA across cellular membranes. It is well known that the absorption of mRNA
in the absence of a delivery system is extremely low, and the half-life of mRNA is approximately
7 h [72]. Moreover, mRNA is an inherently unstable molecule, which is highly prone to degradation
by 5’ exonucleases, 3’ exonucleases, and endonucleases [73]. Consequently, delivery systems are
imperative for intracellular delivery of mRNA to the therapeutic site of action in vitro as well as
in vivo [8,74]. Different strategies have been investigated to improve RNA delivery, including improved
injection strategies such as microinjections [75], RNA patches [76], gene gun-based administration [77],
protamine condensation [78], RNA adjuvants [79], and encapsulation of RNA in nanoparticles consisting
of lipids and/or polymers [80]. Generally, IVT mRNA for cytosolic delivery is formulated with a
delivery system by mixing with a complexing agent [81], which can protect the mRNA against rapid
degradation and facilitate cellular uptake. Although the general dogma in the field is that efficient
carriers are needed for substantially enhancing the in vivo transfection of mRNA, naked mRNA have
been applied in many in vivo studies. Hence, the following section discusses the delivery of naked
mRNA, followed by sections discussing vector-based mRNA delivery [82–85].
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4.2.1. Naked RNA
The simplest administration strategy comprises intramuscular (i.m.) injection of naked mRNA,
and proof of concept was originally demonstrated by in vivo reporter gene expression in mice [24].
Since then, the effectiveness of naked mRNA has been confirmed upon i.m. [86], subcutaneous
(s.c.) [87] or intradermal (i.d.) [88] injections. I.d. and s.c. administration of mRNA has been shown to
mediate healing of various skin diseases and to ameliorate wound healing by in situ expression of
specific proteins in the skin [75,89]. Adopting this approach circumvents several obstacles otherwise
associated with systemic administration of mRNA, e.g., clearance from the bloodstream via the liver,
the kidneys, and the spleen [75]. Very efficient translation of the encoded protein has been shown for
mRNA administered s.c. [90–92]. Interestingly, more efficient translation has at times been measured
when compared to mRNA-loaded nanoparticle-based delivery systems [90,93]. Hence, it circumvents
the need to employ carriers, eventually contributing to reduced cost and potential risk. Another
advantage of administering mRNA-based vaccines via the s.c. route is that both cellular and humoral
immune responses are induced [94] because the mRNA is expressed by both skin-resident DCs [95] and
non-immune cells [96]. However, the outermost stratum corneum layer of the epidermis serves as a tight
barrier to the absorption of topically administered drugs [97]. Heretofore, various approaches have been
adopted to overcome this barrier, including physical (e.g., microporation [98], microneedles [99], and jet
injection [100,101]), active (e.g., electroporation [102], iontophoresis [103], and sonophoresis [104]), and
passive methods (e.g., nanoparticles [105] and liposomes [106]). Electroporation and sonoporation can
transiently permeabilize the skin by means of electric pulses and low-frequency ultrasound, respectively,
for efficient delivery of genes into the skin [107]. Modified mRNA-encoding vascular endothelial growth
factor-A was formulated in citrate-buffered saline without the use of a delivery system and was used
for i.d. vaccination of patients with type 2 diabetes [108]. However, in spite of pronounced, sustained,
dose-dependent and cargo-specific vasodilation, blood flow increase, oxygen-metabolic upregulation,
angiogenesis and neovessel formation in animal models, the vasodilatory and angiogenic activity
did not translate into humans [108,109]. Microneedle-based delivery is also an efficient technique
where micron-sized needle patch/arrays composed of water-soluble polymeric or sugar excipients are
employed, into which the mRNA is incorporated [76]. The patches/arrays provide mechanical strength
needed for the needle to permeate the stratum corneum and penetrate into the viable skin layers.
Following injection, depending upon the type of microneedles, the patches/arrays degrade/dissolve
and the encapsulated drug is released in the interstitial fluid of the skin [75]. Administration of mRNA
by using dissolvable microneedles provides an important advantage, i.e., delivery in a solid dosage
form circumvents the necessity of dealing with mRNA in a liquid dosage form [110], which therefore
eliminates the menace emanating from RNase contamination, along with increasing mRNA stability,
and shelf life [76]. Scavenger receptor-mediated endocytosis and micropinocytosis have been shown
to be the active uptake mechanisms for naked mRNA in immature DCs [16]. However, naked mRNA
displays a short plasma half-life, is prone to ribonuclease degradation, and faces difficulties in entering
the cell. Therefore, delivery systems have been propounded to protect the mRNA and shield its
negative charge.
4.2.2. Viral Vectors
Delivery of mRNA can be mediated by viral and non-viral vectors. Non-viral vectors can further
be categorized into lipid-based delivery systems, polymer-based delivery systems, and lipid-polymer
hybrid systems [111]. For viral RNA delivery, there has been a great deal of interest in the engineering
of adeno-associated viruses to carry nucleic acid cargoes [112]. Genetically-modified viruses are usually
employed for mRNA/gene delivery. The genes of these viruses are partially or fully substituted with
model or therapeutic genes. A benefit of RNA viruses is that they are replicated and expressed locally
in the cytoplasm. Positive strand RNA viruses are distinguished by a genomic sequence that can be
translated directly into proteins of interest by host ribosomes. Notably, alphaviruses (e.g., Sindbis
and Semliki Forest virus) [113], picornaviruses [114], and flavivirus [115] (e.g., Kunjin virus) have
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been employed for mRNA delivery. Various alphavirus vectors can be used to express high levels
of exogenous protein in a wide spectrum of hosts [116]. Commonly used approaches include the
direct substitution of structural genes with heterologous expression or placing the nonstructural
genes downstream of the RNA sub-genomic promoter [117]. However, alphaviruses induce severe
cytopathogenic effects, which restrict their application in gene therapy, although different strategies
can be employed to surmount this challenge [118]. Some of these strategies include engineering
of mutant vectors with mitigated cytotoxicity and temperature-inducibility, and self-inactivating
vectors with point mutations in the nsP2 gene (especially at position 726, 259 and 650) [119]. Sendai
virus (SeV) (murine parainfluenza virus type 1 or hemagglutinating virus of Japan) that belongs to
the Paramyxoviridae family is worth mentioning owing to its popular application as a vector. It is
favored for its high but transient gene expression levels, wide host cell specificity, low pathogenicity,
and strong immunogenicity [120]. As a vaccine platform, the Venezuelan encephalitis virus is of
particular interest [121]. These vaccines encompass the live-attenuated viral vaccine TC-83 and a
formalin-inactivated variety of it is referred to as C-84, which boosts the efficacy and increases the
duration of immunity upon administering the TC-83 vaccine via different administration routes,
intranasal being the most widely used [122]. However, using viral vectors embodies crucial drawbacks
associated with genome integration, and possible host rejection (immunogenicity and cytotoxicity)
among others [123], hence provoking the need for non-viral vectors for mRNA delivery [10].
4.2.3. Polymer-Based Vectors
Diethylaminoethyl (DEAE) dextran was the first polymer to be tested as a delivery reagent for IVT
mRNA [124]. Later, it was shown that lipid-mediated mRNA transfection is 100 to 1000 times more
efficient than DEAE-dextran [125]. This discovery stalled the progress of polymeric carriers and paved
the way for lipid-based transfection reagents for nucleic acids, including mRNA. A comprehensive study
compared the polymers poly-beta-amino-esters (PBAE) and polyethylenimine (PEI) with commercial
transfection reagent Lipofectamine™ 2000 and 1,2-dioleoyl-3-trimethylammonium propane (DOTAP)/
1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) for functional, antigen-specific T-cell responses
after mRNA delivery [126]. All carriers were complexed with mRNA encoding the HIV-1 antigen
gag. Gag-specific, IFN-γ secreting T cells were measured in the spleen and lymph nodes of mice
immunized with gag mRNA complexed with cationic lipids but not in mice immunized with naked
and polymer-complexed mRNA. PEI and its derivatives are among the most commonly employed
cationic polymers [127]. They are water-soluble, display a high density of positive charge associated
with the amino groups, and are proven mRNA carriers for in vitro transfection [128]. However,
PEI displays toxicity issues owing to the high molecular weight (>25 kDa), which may arise from
the adsorption of anionic serum proteins onto the polyplex surface between cationic polymers and
anionic serum plasma proteins. However, the resultant increase in size is only transient as the proteins
adsorbed on the surface of polyplexes prevent particle–particle aggregation in the long run [129].
Various efforts have been made to mitigate these challenges. The first proof of concept for safe
and efficacious mRNA vaccine transfection employing cationic polymer was obtained by intranasal
administration of 2 kDa PEI conjugated to cyclodextrin. Cyclodextrin conjugated to PEI enabled
delocalization of the charge density on the polyamine backbone, hence reducing cytotoxicity and at
the same time maintaining protonatable groups, resulting in improved transfection [130]. Polymeric
nanoparticles composed of biodegradable polymers, e.g., poly(lactic-co-glycolic acid) (PLGA), are well
suited for incorporation of hydrophobic and positively-charged molecules. They provide good colloidal
stability, low toxicity, and the possibility of sustained release. However, due to the anionic nature
of PLGA at physiological pH [131], the mRNA encapsulation efficiency is very low. Polymer-based
carriers exhibit considerable potential for gene therapy owing to the substantial transfection efficiency
and tolerable toxicity [132]. A series of multifunctional block copolymers, i.e., dimethylaminoethyl
methacrylate (DEAMA), poly(ethylene glycol) methacrylate, and DEAEMA-co-n-butyl methacrylate,
demonstrated a transfection efficiency of 77% and 50% in RAW 264.7 macrophages and DC2.4 dendritic
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cells, respectively, thereby exhibiting potential as a carrier for mRNA-based intracellular vaccine
delivery [133]. While different types of polymers and copolymers have been tested, the correlation
between the structure of polymers and their biological response, e.g., transfection and toxicity, was
found to be poor and thus, design of various polymer-based delivery systems relies on empirical, rather
than rational approaches [134]. Despite the advantages mentioned above, polymer-based delivery
systems are not as clinically advanced as lipid-based delivery systems owing to their polydispersity
and challenges pertaining to metabolism of large molecular weight polymers [21].
4.2.4. Lipid-Based Vectors
Vectors based on lipids or lipid-like compounds (lipidoids) represent the most commonly used
non-viral gene carriers [21]. Various synthetic and naturally-derived lipids have been employed to form
liposomes (complexes of liposomes and nucleic acids are referred to as lipoplexes) or lipid nanoparticles
(LNPs), both of which have been reported to efficiently deliver mRNA-based vaccines (Table 2). LNPs
are often formulated by using cationic lipids displaying tertiary or quaternary amines to encapsulate the
polyanionic mRNA. Cationic lipids spontaneously encapsulate negatively-charged mRNA, mediated
by a combination of attractive electrostatic interactions with RNA and hydrophobic interactions, and
thus have been used alone or in combination for lipofection of mRNA. The first reported use of LNPs
as delivery system for mRNA came in 2015, with the delivery system consisting of ionizable cationic
lipid/phosphatidylcholine/cholesterol/PEG-lipid in the ratio of (50:10:38.5:1.5 mol/mol) [86]. Examples
of cationic lipids include e.g., 1,2-di-O-octadecenyl-3-trimethylammonium propane (DOTMA) [135],
DOTAP [136], and zwitterionic DOPE [137,138]. They are structurally denoted by a cationic headgroup,
a hydrophobic tail group, and a linking group in between [139]. However, cationic lipids have been
observed to exhibit pro-inflammatory reactions and undesirable side effects [140]. Therefore, neutral
lipids are also incorporated into cationic liposomes to decrease toxicity and attain high transfection
levels in vivo [106]. The mechanism of LNP-mediated delivery of mRNA is not fully understood,
but LNPs are suggested to be internalized by endocytosis and are attached electrostatically and fused
with the cell membrane via inverted non-bilayer lipid phases [21].
Liposomes are closed membrane structures, which are formed by self-assembly when
phospholipids are dispersed in aqueous systems [141]. They consist of at least one phospholipid bilayer,
which mimics the cell membrane structure enclosing an aqueous core [8]. DOTAP/DOPE at a 1:1 molar
ratio has been reported as an effective transfection agent for mRNA encoding the HIV-1 antigen Gag,
which successfully induced an antigen-specific immune response in vivo in mice [126]. Additionally,
3β-[N-(N’,N’-dimethylaminoethane) carbamoyl](DC)-Cholesterol)/DOPE-based liposomes in a [1:2]
ratio achieved high encapsulation efficiency of enhanced green fluorescent protein (eGFP) mRNA,
along with high eGFP expression in vitro [106]. Furthermore, an additional multi-component LNP
displayed a tumor-suppressant effect when loaded with herpes simplex virus I (HSV I) thymidine
kinase encoding mRNA. The LNPs were composed of DOTAP/Cholesterol [1:1] liposomes along with
1,2-distearoyl-phosphatidylethanolamine (DSPE)-polyethylene glycol (PEG) and DSPE-PEG-anisamide
(AA) [142]. The principle behind their effectiveness may be summarized as a combination of its
electrostatic interactions attributable to opposite charges and hydrophobic interactions with mRNA.
Additionally, the endosomal escape capabilities and self-assembling properties resulting in uniform
layers enclosing polymeric cores also contribute to the wide application of cationic lipids [143]. However,
in vivo studies are more challenging due to the fast elimination of cationic lipids by the mononuclear
phagocytic system [144]. Cationic lipids consisting of only one quaternary ammonium headgroup
pose safety issues such as toxicity and immunogenicity in vitro [145] and in vivo [146]. For instance,
cationic liposomes when administered via the intravenous route may induce hepatotoxicity [147]
and can trigger a strong IFN-γ response in mice resulting in inflammation [148,149]. Furthermore,
positively-charged lipids, e.g., DOTAP and DOTMA, can be neutralized by anionic serum proteins,
leading to toxicity and reduced efficacy [150]. Moreover, challenges like unrestricted protein binding,
colloidal instability, and drug leakage may arise [151].
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Alternatively, new gene delivery vectors containing ionizable lipids [152] and lipid-like materials
termed lipidoids [153] have been introduced to overcome challenges posed by conventional cationic
lipids while retaining their advantageous transfection properties. Ionizable lipids for mRNA
transfection are positively-charged at low pH (which aids in mRNA complexation when it is carried
out in acidic buffer) but are neutral at physiological pH (for reduced toxicity post-injection) [154].
Unlike conventional cationic lipids, these lipidoids display a series of secondary and tertiary amines
allowing for more efficient interactions with mRNA without remarkably increasing the overall charge
of the delivery system [155]. Encapsulation of mRNA in nanoparticles serves to physically protect
nucleic acids from degradation and depending on the specific chemistry can aid in cellular uptake
and endosomal escape [156]. The combination of the ionizable lipid C12-200, cholesterol, DOPE
and C14-PEG2000 at a 3.5:4.65:1.6:0.25 molar ratio, respectively, encapsulating erythropoietin mRNA
(EPO-mRNA) displayed high efficacy in vivo when injected into mice, measured as the cellular
expression of EPO [157]. The emphasis on the nanoparticle platform for mRNA delivery is in part
due to the application of established DNA and siRNA delivery systems.
4.2.5. Lipid-Polymer Hybrid Nanoparticles
Lipid-polymer hybrid nanoparticles (LPNs) have been demonstrated previously to exhibit effective
functional delivery of siRNA in vitro [158] and therapeutic delivery of siRNA in vitro and in vivo [159].
This hybrid delivery system has also shown promising results for delivery of mRNA, with the
mRNA being encapsulated in a hybrid nanoparticle composed of the lipid-like material N1, N3,
N5-tris(2-aminoethyl)benzene-1,3,5-tricarboxamide (TT) in TT3:DOPE:Cholesterol:DMG-PEG2000
(1,2-dimyristoyl-sn-glycerol, methoxypolyethylene glycol) with a polymeric PLGA core [160].
In addition, optimized LPNs consisting of the degradable polymer PBAE, formulated with PEG-Lipid
C14-2000, showed successful delivery of mRNA to the lungs [161]. This, along with reported co-delivery
of siRNA and mRNA with lipidoid polymer hybrid nanoparticles [162], shows that LPNs are an
emerging nucleic acid delivery system. The hybrid formulation is thermodynamically favorable,
with respect to hydrophobic, van der Waal, and electrostatic interactions [80]. Several lipids and
polymers have been investigated to formulate stable nucleic acid lipid particles using this delivery
system. Most common polymers employed are PLGA, polycaprolactone, polylactic acid, or their
combinations, whereas the lipids used include DOTAP, 1,2-dilauroyl-sn-glycero-3-phosphocholine,
1,2-distearoyl-sn-glycero-3-phosphocholine, lecithin, DSPE, and PEG, among others. Structurally,
based on small-angle X-ray scattering and cryogenic transmission electron microscopy, these
nanoparticles are suggested to entail a polymeric matrix core with lamellar lipid structures with
the nucleic acid localized in the core and in the corona [163].
4.2.6. Peptide-Based Vectors
Peptide-based systems for mRNA delivery are gaining momentum due to the versatility peptides
can offer. Peptide-based delivery systems, both alone and in combination with other materials
such as polymers, have been reported in the literature. In a study concerning ovarian cancer therapy,
the commercially available cell-penetrating peptide (CPP) PepFect14 was complexed with eGFP mRNA
via attractive electrostatic interactions [164]. This nanoparticulate formulation was more efficient
in transfecting eGFP mRNA into cells associated with ovarian cancer than commercially available
lipofectamine MessengerMAX. Similarly, the CPP RALA has been used to effectively deliver both
eGFP and OVA mRNA and has been demonstrated to outperform the cationic lipid DOTAP and the
fusogenic lipid DOPE [165]. However, current limitations include targeted cell delivery [164] and short
circulation half-life due to the low stability in serum-containing medium [166].
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Recently, a novel polymer-peptide hybrid mRNA delivery nanoplatform was introduced [167]
combining both polymer (PLA) based micelles and a cationic fusogenic peptide (RALA) to achieve
appropriate degradability, mRNA stability, and endosomolytic properties for translation. It was
reported to protect eGFP as well as FLuc mRNA against serum nuclease degradation and achieve DC
transfection. Indeed, peptide-based vectors and hybrids are promising and interesting additions to the
various existing non-viral carriers for the delivery of mRNA.
Table 2. Examples of nanoparticulate drug delivery systems for mRNA delivery.
Drug Delivery
Systems Composition RNA Disease/Condition References
Polymers Poly(glycoamidoamine) Erythropoietin (EPO)mRNA
Anemia and
myelodysplasia [168]
Polyethyleneimine HIV-1 gag mRNA HIV [169]
Poly(β-amino ester) (PBAE) eGFP mRNA N/A [170]
Triblock copolymer (comprising DMAEMA,
PEGMA, DEAEMA and BMA) eGFP and ovalbumin N/A [171]
DEAE-Dextran Luciferase-encodingmRNA N/A [172]
Lipids DOTAP/DOPE HxB-2 HIV-1 Gagantigen mRNA HIV [126]
DOPE/DC-Cholesterol [2:1] eGFP mRNA N/A [106]
DOTAP/Cholesterol [1:1] liposome with
DSPE-PEG and DSPE-PEG-AA
HSV I Thymidine
kinase mRNA Cancer [142]
C12-200:Cholesterol: DOPE:C14-PEG2000 EPO mRNA N/A [157]
A18 Ovalbumin mRNA Melanoma [173]
cKK-E12 HER2 antibodymRNA Cancer [174]
(6Z,9Z,28Z,31Z)-heptatriaconta-
6,9,28,31-tetraen-19-yl
4-(dimethylamino)butanoate (MC3), DSPC,
cholesterol, and
1,2-dimyristoyl-rac-glycerol,
methoxypolyethylene glycol
(PEG2000-DMG)
Human
erythropoietin [175]
DOTAP/DOPE [1:1] HIV-1 antigen GagmRNA HIV [126]
3β-[N-(N’,N’-dimethylaminoethane)
carbamoyl](DC-Cholesterol)/DOPE (1:2) eGFP mRNA N/A [106]
Lipid polymer
hybrid NPs
TT3:DOPE:Cholesterol:DMG-PEG2000
with PLGA core
Firefly luciferase
(FLuc) mRNA and
eGFP mRNA
N/A [160]
PBAE:C14-PEG2000 FLuc mRNA N/A [161]
PBAE:EDOPC/DOPE/DSPE-PEG Ovalbumin mRNA N/A [176]
PBAE: DOPC, DOTAP, and DSPE-PEG eGFP mRNA N/A [105]
Peptides and
peptide-polymer
hybrids
PepFect14 eGFP mRNA Ovarian cancer [164]
RALA eGFP mRNAOVA mRNA N/A [165]
RALA-PLA eGFPmRNAFLuc mRNA N/A [167]
BMA: butyl methacrylate; DEAE: diethylaminoethyl; DEAEMA: diethylaminoethyl Methacrylate; DMAEMA:
dimethylaminoethyl acrylate; DOPE: dioleoylphosphatidylethanolamine; DOTAP: dioleoyl-3-trimethylammonium propane;
DSPC: dipalmitoylphosphatidylcholine; DSPE-PEG: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[amino(polyethylene
glycol); DSPE-PEG-AA: DSPE-PEG-anisamide; eGFP: enhanced green fluorescent protein; HER2: human epidermal growth
factor receptor 2; HIV: human immunodeficiency virus; HSV: herpes simplex virus; N/A: not applicable; PEGMA: poly(ethylene
glycol) methacrylate; PLGA: poly(lactic-co-glycolic acid); TT: N1,N3,N5-tris(2-aminoethyl)benzene-1,3,5-tricarboxamide; PLA:
polylactic acid.
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4.3. Cell-Specific mRNA Delivery
Cell-specific delivery of mRNA would be beneficial for the development of mRNA-based
therapeutics. This can enhance the delivery of mRNA molecules to the targeted cells and hence
reduce the required mRNA dose, as well as reducing potential off-target effects. It has been reported
that lymphoid organs can be targeted by adjusting the net charge of the formulation [177]. This is
based on the principle of APCs being in the vicinity of T cells in these organs, thus providing
optimal conditions for efficient priming and amplification of T-cell responses. Site-specific delivery of
mRNA-loaded nanoparticles via active targeting has been shown to result in induction of strong effector
and memory T-cell responses, and mediation of potent IFN-α-dependent rejection of progressive
tumors, as observed with RNAs. In another study, cell-specific delivery of FLuc and IL-10 mRNA to
leukocytes (Ly6c+) was achieved by coating the formulated mRNA-containing LNPs with anti-L6c+
monoclonal antibodies [178]. Alternatively, DCs and macrophages express receptors with the ability to
present antigens, e.g., C-type lectin receptors [179], which recognize sugar groups such as mannose-
and fucose-terminated glycans [180] and mediate the endocytosis of mannose-modified nanoparticles.
This has been exploited for transfection of GFP mRNA into DCs by self-assembly of mannose-cholesterol
conjugates with varying PEG units as linkers [181].
5. Conclusions and Future Perspectives
The field of mRNA-based therapeutics spans from protein replacement therapy and gene editing
to vaccination. With the dozens of mRNA-based vaccine candidates currently in pre-clinical and clinical
phases of development, it is evident that the mRNA-based vaccine technology is a promising tool for
the development of novel therapeutic and prophylactic vaccines against infectious diseases and cancer.
However, the multifarious obstacles associated with mRNA’s extremely large size, charge, intrinsic
instability, and high susceptibility to enzymatic degradation hamper the translation of mRNA-based
therapeutics from the bench to the bedside. Therefore, the wider application of mRNA-based
therapeutics is still limited by the need for improved vectors or drug delivery systems. Advanced
delivery systems can be applied to overcome the poor stability, cell targeting, and translational efficiency
of naked mRNA. However, many clinically tested mRNA vaccine candidates are formulated without
any delivery system, which suggests a need for further improvement of delivery systems for mRNA
vaccines. Presently, lipoplexes and lipid-based nanoparticles are mostly used for delivering mRNA.
Additionally, polymers and lipid-polymer hybrid nanoparticles offer great promise in terms of safety,
stability, high transfection efficiency, and low price. Continued advancement in mRNA formulation
and delivery using different nanomaterials can improve the wider use of mRNA for the treatment and
prevention of infectious diseases and cancers.
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